Buclizine Hydrochloride

First generation antihistamine, derived from piperazine with moderate sedative and anticholinergic effects. Antivertigo, antipruritic and antiemetic properties (MK 2019, Mostafa 2011).
Used in the treatment and prevention of travel sickness, and to treat vertigo and migraines (associated with several other drugs) and as an appetite stimulant without documented evidence of its effectiveness (Babu 2011).
Oral administration once a day. Occasional use during travel.

Since the last update we have not found published data on its excretion in breastmilk.

There are very few bibiographical references which are also very old, and it is sold in few countries.

The lack of pharmacokinetic data makes it difficult to accurately predict its possible excretion in breastmilk.

First-generation antihistamines, at high doses, inhibit prolactin secretion (Messinis 1985, Board 1981, Golstein 1979, Wortsman 1979), but the stimulation of infant suction is usually sufficient to ensure breastmilk production (Messinis 1985 ).
No decreases in breastmilk production have been recorded with usual doses of antihistamines.

The occasional use or minimal doses of antihistamines, even first generation, is considered safe during breastfeeding (So 2010), with low frequency of side effects, which are also mild (Ito 1993), so the occasional use of buclizine to avoid travel sickness can be considered compatible with breastfeeding.

Buclizine preparations associated with various medications during breastfeeding are not recommended and there is no evidence that it is effective in treating vertigo or migraines or other conditions.

Monitor drowsiness and the adequate feeding of the infant if this medicine is used during breastfeeding.
It is not recommended to share a bed with the baby if this medication is taken due to an increased risk of suffocation or sudden infant death (UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006).